Aeglea BioTherapeutics appoints Suzanne Bruhn to board
Dr. Bruhn previously served as chief executive officer, president and director at Promedior, Inc., a clinical-stage biotechnology company, from 2012 to 2015.
During her time at Promedior, Dr. Bruhn focused the company’s strategy on clinical development for orphan diseases and negotiated the grant of an exclusive option to acquire Promedior to Bristol-Myers Squibb Company in 2015.
Prior to Promedior, Dr. Bruhn held a number of roles in strategic and portfolio planning, program management and regulatory affairs at Shire Human Genetic Therapies, formerly known as Transkaryotic Therapies, between 1998 and 2012.
She also served on the board of directors of Raptor Pharmaceuticals Corp., a biotechnology company focused on treating rare metabolic disorders, from 2011 until it was sold to Horizon Pharma plc in October 2016.
Dr. Bruhn earned her bachelor’s degree in chemistry from Iowa State University of Science and Technology and her Ph.D. from Massachusetts Institute of Technology. ■
LATEST MOVES FROM Texas
- J. C. Penney elects Wonya Lucas to board
- Xplore Technologies names Robert McFarland to board
- Fossil Group appoints Jeffrey Boyer as CFO
- Houston Wire & Cable elects Roy Haley to board
- Texas Instruments elects Brian Crutcher to board
More inside POST